

European Portfolio Strategist

Risk On — Move On, What Next? Risk...

- **Risk on** — Falling macro risk & rising economic optimism provided springboard for an aggressive [risk rally since late June](#). Risk assets have led, with European equities up 15-20%. Risk & value within risk assets have done even better, eg Banks, Autos. Quality, the structural leader of the past 5-6 years, has lagged.
- **Value expensive, risk not** — The rally has driven an aggressive re-rating of value. Cheap is no longer cheap. The cheapest quintile of European stocks now trade at the top of their 25-year P/E range. Value also trades close to or at record highs against quality & risk-on P/E's and P/B. Risk cheap vs value and vs quality = risk looks cheap.
- **What to do #1** — The stand-out value opportunity = equities vs other assets. Within equities, we think earnings leadership will drive performance leadership in the coming 12-18m. Better macro likely to bring end of downgrade cycle, so investors should own high 2014-15E compound growers, eg Banks, Resources, Travel & Leisure.
- **What to do #2** — Own 're-leveraging optionality', ie companies which can benefit from economic, operational & financial leverage. 2 strategies = surplus FCF & strong balance sheets (quality) and REV (risk), ie barbell. REV = Risk, Earnings Mo & Value = Banks, Insurance & Autos. REV stocks = AXA, ING, Renault, Kering, M&S, GKN.
- **Sector changes** — We have raised exposure to financials, risk & recovery in past 12m vs [more selective in defensive](#) growth. Keep moving. For next 12-18m, we move more pro-cyclical. We lower Health Care/Media to Neutral, Food & Bev to U/weight. We raise Industrials/Real Estate/Retail to Neutral, Basic Resources to Overweight.

Anna Esposito

+44-20-7986-4039
anna.z.esposito@citi.com


Jonathan Stubbs

+44-20-7986-4218
jonathan.stubbs@citi.com

Ayush Tambi

+91-22-4277-5153
ayush.tambi@citi.com

Figure 1. Macro Risk Down- Risk Appetite Up & Risk On



Source: Citi Research, ECB

[24th Oct — Mega-Caps](#)
[3rd Oct — If...*](#)
[19th Sep — Bull Market](#)
[16th Sep — REV It Up](#)
[12th Sep — Roadshow Highlights](#)
[5th Sep — Rerating, Restructure, Recovery](#)
[29th Aug — European Recovery](#)
[15th Aug — The Citi Income Report](#)
[1st Aug — DG vs Fins vs Offensives](#)
[25th July — How to Play Recovery in EU](#)
[18th July — Capital Allocators are Coming](#)

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Contents

Risk On — Move On, What Next? Risk...	3
Valuation Tables	21
Appendix A-1	34

Risk On — Move On, What Next? Risk...

Interrupted by various risk/value rallies, quality has been the structural outperformer in UK/European equity markets in the past 5 years. [The latest risk rally started in late June](#). Both risk assets and risk within risk, e.g. Spanish banks, have ripped. Quality has taken a back-seat. But, it has been a more selective and less extreme version of the 2009 risk trade (aka Survivors' Party).

As always when the sun rises on a new day, investors (and strategists) have to answer the "what to do next" question. We have been, [and remain, \(very\) bullish](#) on equities and have progressively raised exposure to risk (eg financials) and recovery (eg ["How to Play Recovery in Europe"](#)) over the past 12-15 months. We have also lowered exposure to quality/defensive growth.

How does the recent risk/value-led market change our view on how investors should be positioned for the coming 12-18 months? Should investors chase naked risk? Is quality now the value trade? Or somewhere in between, eg barbell?

Our analysis suggests that value has re-rated aggressively, in absolute terms and against both quality and even risk. Now, cheap is not cheap on most measures. In fact, value is at or close to c20-year high valuation multiples on some measures. By contrast, quality has de-rated and now appears cheap on some measures.

Earnings leadership to determine performance leadership

But, ultimately, we think that it will be earnings leadership which determines performance leadership in the coming 12-18 months. That performance leadership should be found in risk, quality and value style buckets where there is also earnings leadership. To us, this suggests a bottom-up, not a top-down, market.

So, as the day dawns, our answer as to "what to do next" is: 1) equities remain attractive with c20+% total returns to end-2014, 2) equity investors need more 're-leveraging optionality' (or beta as a short-cut) than in the era of de-leveraging & 'quality only' leadership, 3) re-leveraging optionality should help to skew to earnings leadership = companies with exposure to economic, operational and financial leverage, 4) be wary of chasing risk only, yield only or value only strategies; look for more substance, 5) overown: a) [surplus FCF & strong balance sheet combos](#), b) REV stocks and sectors, c) restructuring/de-equitisation, d) Citi's European Focus List, which represents a combination of our strategy views and our analysts' high conviction Buys (eg AXA, BNP, ING, Novartis, Rio Tinto, Siemens).

Health Care to Neutral and Food & Beverage to Underweight

Last, we make some changes to our European sector strategy to position for the coming 12-18 months. We also add beta as a factor to our model (10% weight). We lower Health Care to Neutral and Food & Beverage to Underweight. We keep our preference for cheaper Health Care over Food & Beverage. This continues our shift away from defensive growth which started 12-months ago. Both sectors will struggle to be part of the 2014-15 earnings leadership group, in our view, although we continue to like various stocks within these sectors (eg ABInbev, Novartis, Roche).

Real Estate, Industrials & Retail to Neutral

We raise Real Estate, Retail and Industrials to Neutral. Both are scoring well on our sector allocation model; Industrials has good earnings momentum and analysts expect 10% compound earnings growth over the next 2-years from the sector.

Basic Resources to Overweight

Last, we raise Basic Resources to Overweight. We moved the sector up from Underweight in June. Our analysts expect the sector to enjoy the highest 2014-15E compound earnings growth, alongside Technology, Banks and Travel & Leisure. We are already Overweight those three sectors. Roll the tape...


The story so far — quality vs risk/value

Investors who have backed quality (companies) will have enjoyed excellent absolute and relative returns over the past 5-6 years. Figure 2 shows the performance of three quintiles from our Quant team's style analysis — high quality, cheap value, high risk. Value dominated between 2003-07, supported by a leverage fest. Quality has dominated since then.

Quality outperformed Risk and Value in 2007-2011. Since 1Q12 they've moved broadly in line

We have run various quality strategies over the past few years, such as Quality Street, strong in strong, World Champions, Defensive Growth, QARP. But, since late-2011, we have diluted our quality bias with our barbell approach to UK/European equities. The barbell has looked to balance (acceptable) risk with quality, evolving towards more risk/less quality in recent quarters.


Figure 2. Quality Risk & Value — Relative Performance Since 2003 (vs MSCI Equal Weighted)



Source: Citi Research

Figure 2 shows the performance of quality relative to value and to risk. Again, the structural outperformance of quality is clear. But, performance has been similar since 1Q12. From a performance perspective, at least, the structural leadership of quality appears to have come to an end. Is there any fundamental support for this?

Figure 3. Quality — Performance Rel to Value & Risk Since 2003




Source: Citi Research

Springboard for risk — better macro

Falling macro risk has been the foundation of our bullish view on equities and on higher exposure to risk and recovery within equity markets in recent quarters. It has also been the springboard for the recent risk/value surge in UK and European equity markets.

Higher PMIs in Europe (Figure 4) were a key factor driving our support for European recovery trades in July this year. Improving Chinese macro data, eg stronger CESI, has also helped (cheap) EM equities to perform strongly in recent months.

Figure 4. Euro Area & UK PMI



Source: Haver Analytics


Figure 5. China CESI



Source: Datastream

Figure 6 shows another way of assessing macro risk — the ECB's composite indicator of systemic risk. This is constructed largely from a variety of financial market indicators. The indicator is at its lowest implied risk level since inception in 1999. It clearly shows the sharp fall in macro risk, that we can also highlight through improvements in peripheral current account positions, European bank capital and the US fiscal deficit.

Figure 6. ECB Composite Indicator of Systemic Stress



Source: ECB


Falling macro risk a key driver of pick-up in risk appetite

Falling macro risk has, in our view, been a key driver in the synchronised pick-up in risk appetite from key economic actors: 1) capital allocators, 2) corporates, 3) investors, 4) consumers. The animal spirits are starting to emerge and to normalise. Since late-June, this has helped risk to perform strongly.

Risk on — leaders and laggards


It has paid investors to take on risk in most areas in the past few months. Figure 7 shows the performance of key asset classes since 24th June this year. Europe ex-UK equities have been the best performing major asset class in this time and are up c20% in the last few months; a healthy return gap over c0% cash. EM equities and UK mid-caps have followed close behind. There is a big return drop-off to other asset classes, where high yield, ie fixed income risk, leads the also-rans.

Figure 7. Asset Returns, Since 24th June



Source: Datastream

Figure 8. Style Performance




Source: Citi Research

Figure 8 shows the leading and lagging style performers since 24th June, using our Quant team's style indices. Value, GARP and Risk (ie opposite of Low Risk) have been the best performers in the last few months. Our Quant team run long-short quintiles for each style. Risk and value have led. But, it is also interesting to note that investors would have enjoyed small positive returns via Earnings Momentum and the negative returns from quality would have also been only small. This

appears to have not been a rout for fundamentally-based strategies, ie earnings, RoE, balance sheets.

Figure 9. Relative Returns By Earnings Momentum Quintile



Source: Datastream & Citi Research


Both strongest and weakest E Mo outperformed

Our analysis, using our Forecast Monitor earnings database, backs up this result. Figure 9 shows the average post-24th June relative return for European quintiles based on earnings momentum trends in June.

Owning the best earnings momentum stocks, i.e. top quintile, in June to now would have delivered decent outperformance. This is partly due to inflection in European Financials' earnings over the last 12-months, from negative to positive. With Autos also showing positive earnings momentum relative to the market, earnings momentum investors would have owned some risk/value sectors over the past few months.


But, owning the worst earnings momentum stocks has performed better still. Both top and bottom quintiles would have beaten the rest. So, investors running a barbell of positive and negative earnings momentum stocks would have performed very well indeed.

Figure 10. Top 5/Bottom 5 Country Returns



Source: Datastream

Figure 11. Top 5/Bottom 5 Stoxx Sector Returns




Source: Datastream

The risk/value trade can also be clearly seen elsewhere. The importance of improving Euro Area macro sentiment is shown in the country and sector leadership of the last few months. Greece, Spain, Italy and Ireland have all been leading performers since end-June, with Spain and Italy being the big turnaround stories having been significant underperformers vs. the rest of Europe in 1H13.


Banks, Financial Services and Autos (part Financial) joined Media and special-situation Telcos as the leading sectors. Quality and defensive growth markets and sector performed well in absolute terms, but lagged significantly in relative terms.

Figure 12. Top 5/Bottom 5 UK Sector Returns



Source: Datastream

Figure 13. Top 7/Bottom 7 FTSE 100 Returns



Source: Datastream


Latest risk rally has not been one-dimensional

The risk/value rally has also been seen in the UK, but with one key difference. European banks have led the recent rally. UK banks have lagged. The strong performance of Telecoms also shows clearly with Vodafone and BT both strong performers since June. Other defensive sectors have otherwise generally been laggards, but that has not stopped some stocks, such as Shire, performing strongly. Again, this shows that the latest risk rally has not been as one-dimensional as some previous ones in the last few years.

What next?


So, risk and value have been on a charge. What should investors do next? Before looking for an answer, we look at how recent performance trends have changed valuations at an asset level and within equity markets by country, style and size.

Figure 14. MSCI Europe — P/E



Source: Datastream

Figure 15. MSCI UK — P/E



Source: Datastream

PE above LT average...

Figure 14 and Figure 15 show the long-run trailing P/Es for UK and European equity markets. The recent re-rating has driven P/Es to above 40-50 year average levels. This suggests that equities are no longer cheap and will need good news, eg profit growth, to sustain further upside from here. We think that happens in 2014-15E.


This also explains why investors (and analysts) are finding it increasingly difficult to find value in the market, especially when the cheapest part is concentrated in a few heavyweight stocks, ie mega-caps.

Figure 16. European Corporate EYR



Source: Datastream & Citi Research

Figure 17. Long Term UK DYR (vs Sovereign)



Source: Global Financial Data & Datastream


...But equities cheap against credit and government bonds

Figure 16 and Figure 17 compare equities to credit and government bonds. Despite recent strong performance, equities still look very attractive relative to fixed income (and cash). Unless interest rates normalise aggressively and quickly, which we think is unlikely, then equities continue to present the outstanding (relative) value opportunity for global investors. Citi's global asset allocation team, led by Jeremy Hale, agrees. [They remain Overweight equities.](#)

Southern comfort


Next, we turn to within equities. First, countries. Peripheral equity markets have led the post-June charge. Reducing macro risks across the periphery and the Euro Area has been a strong driver of this performance. Even Italian politics was unable to derail these recent moves.

Figure 18. South P/E Rel to North



Source: Datastream & Citi Research

Figure 19. South P & E Rel to North




Source: Datastream & Citi Research

Figure 18 and Figure 19 shows the sharp re-rating that Southern Europe, ie the peripheral markets, have enjoyed relative to the North. The South now trades on 5-year P/E relative highs versus the North.

Recent price performance has not been supported by earnings outperformance from the South. That is what we think is needed for recent performance to become more structural. That would likely need a stronger economic recovery than our economists expect within the periphery or across the Euro Area. We don't think that investors should be taking aggressive country positions from here. For exposure to value and to an improving economy in Europe, we would continue to prefer to be Overweight Financials rather than peripheral equity markets.

Figure 20. P/Book By RoE By Country



Source: Datastream


Value to be found in a mix of Southern and Northern markets

Figure 20 compares European countries' current price/book multiple and 2013E RoE. There is reasonable correlation between the two factors. This would suggest that there is value in a mix of Southern (e.g. Italy, Spain) and Northern (e.g. Germany, UK) markets rather than a big divide between the two groups. With a reduced macro risk backdrop, the previous structural leadership of long North/short South could well be at an end. This is reinforced by the bond yield spread forecasts of our rate strategists for Italy and Spain. They are targeting 10-year spreads versus Germany to move below 200 basis points over the coming 12-18 months.

Cheap is not cheap


The strong risk/value rally has left its mark on style valuation charts. The following charts have been core to our evolving views over the past few years as we have looked to assess where the value is within European equities.

Figure 21. Cheapest Quintile — 12m Fwd P/E



Source: Datastream & Citi Research

Figure 22. Cheapest Quintile — P/E Rel




Source: Datastream & Citi Research

Cheap no longer cheap

Figure 21 shows the average 12-month forward P/E for the cheapest quintile of European stocks over the past 25 years; this is a dynamic universe. The group has traded in a P/E range of 4-10x. We are currently at the top end of the 25-year range. The cheapest stocks in Europe have rarely been more expensive in absolute P/E terms. Figure 22 shows the same group relative to the rest of the market. Similar story. The cheap part of the market looks expensive in relative terms compared to


the last 25 years. Only more expensive at the end of the super-charged leverage years of 2003-07 and at the end of the violent 2009-10 recovery rally.

Figure 23. Most Expensive — 12m Fwd P/E



Source: Datastream & Citi Research

Figure 24. Most Expensive vs Cheapest Quintile



Source: Datastream & Citi Research

Figure 23 shows the average 12-month forward P/E for the most expensive quintile of European stocks. This group has also been re-rated in the last year from 20x to 24-25x. That sounds expensive, but is mid-range compared the last 25 years when excluding the TMT boom years.

This means that when comparing expensive cheap to mid-range expensive expensive, you get cheap expensive. Confused? Figure 24 should help. This plots the expensive quintile relative to the cheap quintile. The expensive group is actually trading close to 25-year lows relative the cheap group. So, while cheap is not cheap in absolute terms, expensive is cheap in relative terms.

What happens next? We continue to believe that there will be strong performance from both the cheap and expensive groups above; much of that will depend on the earnings performance from the companies themselves. This is why we are happy to be Overweight both the most expensive sector in the market (Technology) as well as the cheapest (Autos), based on 2013E P/Es.

Figure 25. Largest 10 Cheapest Stocks

Stock	RIC	Mkt Cap	Current 12m Fwd P/E
HSBC Holdings	HSBA.L	149148	10.7
BP	BP.L	104572	8.2
Total	TOTF.PA	101482	8.6
Royal Dutch Shell A	RDSa.L	96089	8.6
Daimler	DAIGN.DE	58747	11.0
BNP Paribas	BNPP.PA	56621	10.3
Allianz	ALVG.DE	55978	9.2
Telefonica	TEF.MC	51638	11.8
ENI	ENI.MI	48460	10.5
AstraZeneca	AZN.L	48266	10.6

Source: Datastream & Citi Research

Figure 25 shows the 10 largest constituents of the cheap quintile; all mega-caps. Valuation may be cheap for most of these stocks, but our analysts see different pressures/risks and opportunities in the coming 1-2 years. For example, our report on mega-caps last week highlighted the oil majors and Telefonica as potential value traps for investors. For example, our Telecoms team has [downgraded Telefonica to Sell](#) in a recent report.


On the other hand, we highlighted the likes of Daimler, Allianz and BNP as offering investors what we think is an attractive combination of exposure to recovery and restructuring. Both Allianz and BNP remain on the European Focus List.

So, rather than blindly buying the whole cheap group here, we think that investors, in a world with low macro volatility, should be doing more bottom-up homework. But, if the macro backdrop is improving, which we think it is, then it should also pay investors to run a more pro-cyclical portfolio over the coming 12-18 months. That is where earnings leadership is more likely to come from. That also means that defensive industries may face some relative headwinds. We try to reflect this in our European sector strategy and in further changes we make to that today.

Quant style


Investors cut equity markets in different ways in order to get more complete information — eg by region/country, by sector, by stock. We think style analysis adds an important further layer of analysis for all equity investors. This is why we spend a lot of time discussing style performance and valuation with our excellent [Quant team, led by Chris Montagu in London](#). The following charts use their style indices to compare where three quintiles trade in terms of P/E and price/book — cheap value, high quality, high risk.

Figure 26. Value vs Quality P/E Relative



Source: Citi Research


Figure 27. Value vs Quality P/E



Source: Citi Research


Figure 26 shows the sharp re-rating of cheap value relative to high quality in the last few months. It pales in comparison to the same move in 2009, but is one of the biggest re-ratings of value vs. quality that has happened in the last c20 years. Value now looks expensive on this basis.

Figure 28. Value vs. Quality P/Book



Source: Citi Research

Figure 29. High Quality vs. Low Qual. P/B Rel




Source: Citi Research

Value has never been so expensive against Quality

Figure 28 shows the same pair on a price/book basis. The move has been more extreme. The re-rating of value vs quality in the last 12-18 months has actually exceeded the 2009 re-rating. Value has never been so expensive vs quality on this basis in the last c20 years. Investors putting fresh money into equities today with a pure value bias probably need to have high conviction over a sizeable improvement in economic activity in Europe and globally over the coming 1-2 years. The other side of value looking expensive is quality looking cheap. Figure 29 makes this point


another way by showing that high quality is trading around decade cheaps vs low quality on a price/book basis, using the Quant team's style data.

Figure 30. Value vs Risk P/E



Source: Citi Research


Figure 31. Value vs Risk P/Book



Source: Citi Research


Back to value, Figure 30 and Figure 31 show that value also now looks expensive relative to risk, at or beyond c20-year record levels on both a P/E and price/book basis. So value has re-rated vs both quality and also against risk.

Figure 32. Value vs Value P/E



Source: Citi Research

Figure 33. Value vs Value P/Book




Source: Citi Research

Risk still cheap against Quality


Figure 32 and Figure 33 complete a thorough look at the valuation of value. They show the cheapest value quintile relative to the most expensive value quintile on both a P/E and price/book basis. Reassuringly, we get similar results to our quintile analysis on cheap and expensive from earlier in the report. Figure 32 here shows that cheap value has never been more expensive on a P/E basis and is close to, although not at, record highs on a price/book basis.

Figure 34. Risk vs Quality P/E



Source: Citi Research

Figure 35. Risk vs Quality P/Book



Source: Citi Research

Figure 34 and Figure 35 contrast the two non-value quintiles — high risk and high quality. Risk is a combination of debt/equity, earnings stability and beta. Risk hit relative valuation lows vs quality in late-2008/early-2009, re-rated aggressively

before de-rating back to late-2011/early-2012 lows. Over the past year and a bit, risk has enjoyed a gradual re-rating vs quality, due largely to improved performance from European financials. But, these charts, and the earlier value vs risk ones, suggest that it is risk that looks cheap vs quality (and value), rather than value. This a key reason behind our REV strategy, which focuses on stocks with exposure to Risk and Earnings momentum, as well as to Value. We think this is a better way of positioning for improving economic activity in the next 1-2 years. We look in the next section what stock implications this has.

What to do? = barbell = risk & quality

Our analysis suggests that value has re-rated aggressively. Now, cheap is not cheap on most measures. In fact, value is at or close to c20-year high valuation multiples on some measures. By contrast, quality has de-rated and now appears cheap on some measures. Risk looks cheaper still.

Bottom-up, not top-down, market

But, ultimately, we think that it will be earnings leadership which determines performance leadership in the coming 12-18 months and that performance leadership will be found in risk, quality and value style buckets where there is also earnings leadership. To us, this suggests a bottom-up, not top-down, market.

So, as the day dawns, our answer as to "what to do next" is: 1) equities remain attractive with c20+% total returns to end-2014, 2) equity investors need more 're-leveraging optionality' (or beta as a short-cut) than in the era of de-leveraging & 'quality only' leadership, 3) re-leveraging optionality should help to skew to earnings leadership = companies with exposure to economic, operational and financial leverage, 4) be wary of chasing risk only, yield only or value only strategies; look for more substance, 5) overown: a) surplus FCF & strong balance sheet combos, b) REV stocks and sectors, c) restructuring/de-equitisation, d) Citi's European Focus List which represents a combination of our strategy views and our analysts' high conviction Buys (eg AXA, BNP, ING, Novartis, Rio Tinto, Siemens).


Looking for earnings leadership

Before digging into our 'overown' strategies, we suggest where investors may find earnings leadership in the next 1-2 years in Europe.

We believe that improving macro conditions will progressively end the current earnings downgrade cycle. We are not suggesting that there is a new upgrade cycle to come, but that it is more likely that analysts' earnings estimates are hit in the next 1-2 years compared to the previous 1-2 years.

With that assumption, Figure 36 becomes quite important. It compares the 2013E P/E of European sectors to their 2014-15E compound earnings growth rates, according to Citi analysts. Making a heroic assumption that all analysts' earnings estimates are hit would suggest that those sectors above the best-fit line are attractively value for their prospective earnings and those below the line are not.


Figure 36. European Sector — EPS Growth vs P/E 2013



Source: Datastream & Citi Research

Broadly, and post the sector changes at the end of this note, this is how we have been and continue to be positioned. In our latest sector changes we further reduce exposure to defensive sectors. We are not making an absolute call here. We are merely suggesting that most of these sectors are unlikely to offer enough earnings growth to be in the new leadership group of the next couple of years.

Figure 37. UK Sector — EPS Growth vs P/E 2013



Source: Datastream & Citi Research

Figure 37 repeats this analysis for UK sectors. Here, we are already Underweight only defensive sectors, such as Electricity, Food Retail, Gas/Water, Oil & Gas, Pharma. We remain Overweight Beverages in the UK, where our analysts like Diageo, but otherwise also have a pro-cyclical and pro-financial Overweight skew.

Surplus FCF and strong balance sheets

Our first 'overown' group is stocks with surplus FCF and strong balance sheets. This generally remains a quality strategy. Warren Buffett finds both of these attributes very attractive. So do we. We like the optionality from both factors. Surplus cash and strong balance sheets are nice problems to have. Some of these companies can deliver bigger dividends or buybacks (eg Next). Other companies could also find these qualities attractive should M&A activity pick-up. All these attributes can also be found in our long-running theme of [World Champions](#).

Figure 38. Companies with Average 2013E-2015E FCFY >200bps above DY & Net Debt/EBITDA <1x (Mkt Cap >€5bn)

Stock	RIC	Stock	RIC	Stock	RIC
ABB	ABBN.VX	Essilor Intl.	ESSI.PA	Richemont N	CFR.VX
Aberdeen Asset Man.	ADN.L	GKN	GKN.L	Rio Tinto	RIO.L
Actelion	ATLN.VX	Henkel Pref.	HNKG_p.DE	Roche	ROG.VX
Adecco R	ADEN.VX	IMI	IMI.L	Ryanair Holdings	RYA.I
Ahold Kon.	AHLN.AS	ITV	ITV.L	Sanofi	SASY.PA
Alfa Laval	ALFA.ST	Kering	P RTP.PA	SAP	SAPG.DE
ASML Hldg	ASML.AS	Kingfisher	KGF.L	Schneider Electric	SCHN.PA
Assa Abloy B	ASSAb.ST	Kuehne+Nagel Intl.	KNIN.VX	Shire	SHP.L
AstraZeneca	AZN.L	Legrand	LEGD.PA	Siemens	SIEGn.DE
Atlas Copco A	ATCOa.ST	LVMH	LVMH.PA	Smith & Nephew	SN.L
Bayer	BAYGn.DE	Merck KGAA	MRCG.DE	Smiths Group	SMIN.L
Beiersdorf	BEIG.DE	Michelin	MICP.PA	Sodexo	EXHO.PA
BHP Billiton	BLT.L	Next	NXT.L	Swatch B	UHR.VX
BSkyB	BSY.L	Nokia	NOK1V.HE	Unilever (UK)	ULVR.L
Burberry Group	BRBY.L	Novartis R	NOVN.VX	Unilever Certs.	UNC.AS
Coloplast 'B'	COLOb.CO	Novo Nordisk B	NOVOb.CO	Valeo	VLOF.PA
Continental	CONG.DE	Philips Electronics	PHG.AS	WPP	WPP.L
Dassault Systemes	DAST.PA	Randgold Resources	RRS.L	Yara International	YAR.OL
Deutsche Boerse	DBGn.DE	Reckitt Benckiser Group	RB.L		

Source: Citi Research

Figure 38 shows those European companies with an average 2013-15E FCF yield at least 200 basis points above the respective DY for the same period and with net debt/EBITDA below 1x.

REV it up

Our second 'overown' strategy is REV. We introduced our REV strategy in September to raise exposure to risk supported by fundamentals; in this case positive earnings momentum. Then, we highlighted Banks, Insurance and Autos as the three clear REV sectors in Europe. Still are.

Figure 39 shows those European REV stocks with a beta above 1.1, positive earnings momentum relative to the market over the last 6 months (>3%) and a 12m forward P/E of 14.5x, ie the median P/E in the market. Our three core REV sectors are well represented, as are various other cyclical.

Figure 40 shows the other side of the REV strategy — low beta, negative earnings momentum and expensive P/Es. The stocks are much more defensive.

Figure 39. Screen of Stocks With High Beta, Earnings Mo and Cheap (Mkt Cap > €5bn)

Stock	RIC	>€5bn Mkt Cap Em	>1.1 Beta	>3 -6m Rel Earn Mo	<14.5 12m Fwd P/E
Daimler	DAIGn.DE	58747	1.2	11.2	11.0
Allianz	ALVG.DE	55978	1.2	10.2	9.2
Lloyds Banking Group	LLOY.L	38975	1.1	44.2	12.4
Prudential	PRU.L	37940	1.6	10.9	13.8
AXA	AXAF.PA	37284	1.5	7.7	8.6
ING Groep	ING.AS	36058	1.6	3.1	8.6
Credit Suisse R	CSGN.VX	34256	1.3	3.7	10.1
Schneider Electric	SCHN.PA	34197	1.2	5.2	13.9
Societe Generale	SOGN.PA	32589	1.9	12.9	9.6
EADS	EAD.PA	28643	1.3	14.1	14.2
Nordea Bank	NDA.ST	27572	1.3	4.4	10.8
BMW	BMWG.DE	26428	1.1	4.4	10.4
Intesa Sanpaolo	ISP.MI	25425	1.5	3.1	13.5
Assicurazioni Generali	GASI.MI	22847	1.2	6.1	11.8
Svenska Handbkn	SHBa.ST	16442	1.3	3.4	12.6
Legal & General	LGEN.L	14718	1.4	11.5	12.7
SEB A	SEBa.ST	14161	1.4	8.0	12.1
Renault	RENA.PA	13253	1.7	4.2	7.8
Continental	CONG.DE	13124	1.4	12.3	11.6
Kering	PRTP.PA	12630	1.2	4.2	14.5
DNB	DNB.OL	12026	1.7	4.6	10.1
Seadrill	SDRL.OL	12007	1.1	6.7	12.8
Aegon	AEGN.AS	10430	1.3	4.7	8.9
Standard Life	SL.L	10134	1.8	5.7	14.2
Credit Agricole	CAGR.PA	9630	1.7	8.8	7.7
Marks & Spencer Group	MKS.L	9066	1.2	5.0	13.3
KBC Groupe	KBC.BR	8338	1.5	3.7	9.8
HeidelbergCement	HEIG.DE	8158	1.4	10.4	13.2
Cap Gemini	CAPP.PA	7622	1.1	9.2	14.4
Christian Dior	DIOR.PA	7538	1.5	4.6	12.4
GKN	GKN.L	7037	1.4	12.3	12.0
Aberdeen Asset Man.	ADN.L	6265	2.0	8.1	13.8
Resolution	RSL.L	5792	1.4	6.4	13.2
Skanska B	SKAb.ST	5757	1.4	5.2	13.7
Weir Group	WEIR.L	5751	1.2	5.1	14.0
Valeo	VLOF.PA	5228	1.4	14.1	12.3

Source: Citi Research

Figure 40. Screen of Stocks With Low Beta, Earnings Mo and Expensive (Mkt Cap > €5bn)

Stock	RIC	>€5bn Mkt Cap Em	<1 Beta	<3 -6m Rel Earn Mo	>14.5 12m Fwd P/E
Nestle R	NESN.VX	171833	0.6	-1.2	18.0
British American Tobacco	BATS.L	77266	0.8	0.4	14.5
Deutsche Telekom	DTEGn.DE	35833	0.7	-0.4	16.3
Danone	DANO.PA	32586	0.8	-3.3	17.9
Air Liquide	AIRP.PA	31671	0.7	1.5	17.6
Syngenta	SYNN.VX	27748	0.5	-6.8	16.4
Pernod-Ricard	PERP.PA	18263	0.7	-2.9	16.3
Tullow Oil	TLW.L	9866	0.6	-21.8	25.1
SGS N	SGSN.VX	9401	0.6	-1.4	21.5
Geberit R	GEBN.VX	7723	0.7	1.7	21.3
Sodexo	EXHO.PA	7038	0.7	-0.4	19.1
Brenntag	BNRGn.DE	6373	0.6	-3.4	16.8
Intertek Group	ITRK.L	6178	0.8	0.4	20.8
Dassault Systemes	DAST.PA	5677	0.3	-0.5	22.9
GBL	GBLB.BR	5292	0.8	-5.7	14.5
Kuehne+Nagel Intl.	KNIN.VX	5216	0.6	1.7	20.7
Randgold Resources	RRS.L	5109	0.4	-38.7	19.4

Source: Citi Research

Sector strategy — more cyclical/less defensive

We have been, and remain, (very) bullish on equities and have progressively raised exposure to risk (eg financials) and recovery (eg "How to Play Recovery in Europe") over the past 12-15 months. We have also lowered exposure to quality/defensive growth. We continue these moves in some sector strategy changes today.

Adding Beta to our model

Figure 41 shows our European Sector Allocation Model (SAM). We re-introduce beta into the model with a 10% weight. We continue to skew heavily towards earnings momentum and surplus FCF, as we do towards US and European exposure to capture improving macro in advanced economies. We include 2 risk factors — slowing EM growth and US tapering/rising bond yields. EM exposure is a reverse factor, ie high EM exposure scores badly. For bond yields, we look at correlation to rising bond yields.

Figure 41. Sector Attribution Model

	EM Exp	US Exp	EU Exp	Earnings Mo	P/B	Abs P/E Rel to 5yr History	B/S	DY*G	FCF-DY	US Bond Yields	Beta	Overall Rank
Factor Weight	5%	10%	10%	15%	10%	5%	10%	5%	15%	5%	10%	100%
Insurance	2	12	4	4	1	16	-	9	-	6	4	6.5
Automobiles & Parts	12	6	13	2	9	1	6	2	14	2	2	6.9
Banks	10	15	8	10	6	5	-	1	-	3	1	7.6
Personal & H/hold	16	9	14	4	16	2	3	5	4	14	9	8.2
Travel & Leisure	5	5	6	4	17	4	10	13	8	11	10	8.3
Technology	18	7	16	1	8	13	1	18	6	5	13	8.3
Real Estate	1	19	1	7	7	8	-	14	-	12	7	8.3
Construction & Materials	7	11	9	11	5	12	13	6	9	4	6	8.9
Financial Services	14	2	19	9	10	17	-	4	-	7	5	9.2
Industrial G&S	13	13	10	8	18	6	4	7	7	8	8	9.3
Retail	8	16	3	3	11	11	5	12	13	16	11	9.4
Health Care	6	1	18	11	13	15	6	8	1	18	19	9.9
Basic Resources	19	14	17	19	2	14	8	17	3	1	3	10.3
Oil & Gas	9	4	11	16	3	3	2	15	16	9	17	10.3
Media	3	3	7	17	12	19	12	16	5	13	15	10.8
Utilities	4	17	2	14	4	10	14	19	15	17	14	12.0
Chemicals	15	10	12	14	19	7	9	11	12	10	16	12.7
Food & Beverage	17	8	15	13	15	9	11	10	10	19	18	12.9
Telecommunications	11	18	5	18	14	18	14	3	11	15	12	13.0

Source: Citi Research

Figure 42 shows our current sector strategy including changes in this report. It should, and does, overlap well with our sector model. We are Overweight the top 6 sectors in SAM, with the three REV sectors scoring best in the model. We are Underweight 5 of the bottom 6 sectors in SAM; Media is the odd-one out, but which we lower to Neutral from Overweight following strong performance and to fund Basic Resources to Overweight.

Figure 42. European Sector Strategy (Arrows Denote Latest Changes)

Overweight	Neutral	Underweight
Autos	Health Care↓	Chemicals
Basic Resources ↑	Media ↓	Construction
Banks	Industrial G&S ↑	Food & Beverage ↓
Financials Services	Real Estate ↑	Oil & Gas
Insurance	Retail ↑	Telcos
Personal & Household Gds		Utilities
Technology		
Travel & Leisure		

Source: Citi Research

Overall, we lower Health Care to Neutral and Food & Beverage to Underweight. We keep our preference for cheaper Health Care over Food & Beverage. This continues our shift away from defensive growth which started 12-months ago.

Both sectors will struggle to be part of the 2014-15 earnings leadership group, in our view, although we continue to like various stocks within these sectors (eg ABInbev, Novartis, Roche).

We raise Real Estate, Retail and Industrials to Neutral. Both are scoring well on our sector allocation model; Industrials has good earnings momentum and analysts expect 10%+ compound earnings growth over the next 2-years from the sector. Exposure to an improving global economy should not hurt.

Last, we raise Basic Resources to Overweight. We moved the sector up from Underweight in June. Our analysts expect the sector to enjoy the highest 2014-15E compound earnings growth, alongside Technology, Banks and Travel & Leisure. We are already Overweight those three sectors.

Special mention — Overweight Financials

Financials Sector remains the biggest Overweight

Despite the recent outperformance, we remain positive on [European Insurance](#) and [Banks](#). Financials sectors also remain the biggest Overweight within our regional and global strategists' portfolios. They both trade on a P/E discount to the market and have positive relative earnings momentum.

Within Insurance, our analysts continue to see attractive valuation upside and believe the macro outlook will be supportive for the sector. Within European Banks, our Banks' team expects AQR (Asset Quality Review) to 'speed-up' the healing process. Banks with relatively higher levels of problem assets and lower coverage are most at risk of potential capital rebuild. These include mid-cap Spanish, Italian, Greek, and to a lesser extent, Austrian banks. They also see the sector passing through an inflection point on capital (from a 2011 capital deficit of €300bn to break-even in 2013E). French, Nordic, and Swiss banks are best placed for capital return (BNP Paribas, Danske Bank, Nordea, Credit Suisse and UBS).

They also like the [UK Banks](#), preferring international banks (HSBC, Standard Ch. and Barclays), where performance has been softer due to their EM exposure, over more expensive (Lloyds) or more structurally challenged (RBS) domestic names.

While Citi analysts are optimistic on Nordic, French, Swiss and UK banks, they are cautious on [Italian](#) and [Spanish Banks](#), where the market has priced in too much optimism in their view. Our Italian Banks analyst thinks market has run too far, as Italian implied cost of equity is now similar to Nordic banks. As such, valuations seem too optimistic. Our Spanish Banks analyst is also wary of the recent rally, which has been mostly based on re-rating.

We don't want to chase the risk rally in European Financials, but would be happy to own higher quality Banks and Insurers into the next 12-18 months.

Strategy outlook

Structural performance trends of past 4 years reversed in past 4 months. Risk & value = ripped. Quality = lagged. Value re-rated & now looks expensive vs quality & risk. Risk still looks cheap. What to do? Most attractive value trade = equities vs other assets. In equities, investors should position now for earnings leadership in the coming 12-18m. Likely to be long cyclicals/financials & short defensives. Stick with our REV strategy = Banks, Insurance and Autos.

This page is left intentionally blank

Valuation Tables

Figure 43. Pan-European Sector Weightings & Returns

As at Close 29 Oct 13 Sector (No of Stocks)	Mkt Cap (Euros m)	% of Return Relative to DJ Stoxx					Absolute Return			
		Stoxx	1m	3m	12m	Ytd	1m	3m	12m	Ytd
Oil & Gas (32)	531,566	8.0	0	-1	-15	-9	3	6	4	7
Chemicals (25)	326,755	4.9	-1	-1	-2	-5	2	7	20	12
Basic Resources (22)	225,795	3.4	-1	4	-22	-23	2	12	-4	-10
Construction & Materials (21)	149,207	2.3	0	2	9	3	3	10	33	21
Industrial G&S (105)	719,912	10.9	-2	0	4	2	1	8	27	20
Automobiles & Parts (14)	189,319	2.9	-2	1	22	11	1	8	49	31
Food & Beverage (29)	543,063	8.2	-1	-3	-8	-6	2	4	13	10
Personal & H'hold Goods (30)	383,031	5.8	-1	-4	0	-1	1	4	22	16
Health Care (34)	734,737	11.1	-1	-5	-2	1	2	3	20	19
Retail (28)	226,496	3.4	0	1	4	5	2	9	27	24
Media (26)	165,071	2.5	2	3	15	12	5	11	41	32
Travel & Leisure (21)	92,421	1.4	-1	-6	6	1	2	1	30	19
Telecommunications (23)	352,118	5.3	3	11	7	14	6	19	32	34
Utilities (26)	269,522	4.1	0	2	-10	-4	3	10	10	13
Banks (47)	875,422	13.3	2	2	6	3	5	10	29	21
Insurance (35)	412,223	6.2	4	1	12	8	7	9	38	27
Real Estate (26)	89,773	1.4	2	-2	-7	-6	5	6	14	11
Financial Services (32)	105,116	1.6	1	1	15	11	4	9	41	31
Technology (24)	213,339	3.2	-4	1	10	3	-2	9	34	21
Stoxx - Pan Europe (600)	6,604,888	100.0	—	—	—	—	3	8	22	18
Pan Euro - Large Cap	5,346,540	80.9	0	0	-1	-1	3	7	21	17
Pan Euro - Mid Cap	862,196	13.1	0	1	4	3	3	9	27	21
Pan Euro - Small Cap	396,152	6.0	1	2	4	3	4	10	27	22
Stoxx ex UK - Europe ex UK (415)	4,445,498	67.3	—	—	—	—	3	9	26	20
EuroStoxx - Eurozone (292)	3,029,206	45.9	—	—	—	—	4	11	28	21

Source: Citi Research & DataStream

Figure 44. Pan-European Sector Relative Ratings

As at Close 29 Oct 13 Sector	P/E Relative to DJ Stoxx				Yield Relative to DJ Stoxx			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Oil & Gas	63	75	75	81	134	132	126	120
Chemicals	104	109	116	113	81	79	80	79
Basic Resources	88	94	91	85	108	97	94	90
Construction & Materials	109	119	111	106	93	94	94	92
Industrial Goods & Services	110	114	112	111	81	83	84	83
Automobiles & Parts	61	71	70	66	87	88	91	92
Food & Beverage	127	130	137	139	82	84	85	83
Personal & H'hold Goods	121	120	123	123	77	81	81	82
Health Care	99	107	109	110	95	94	95	92
Retail	118	121	124	126	88	86	85	83
Media	105	118	120	122	113	100	99	94
Travel & Leisure	141	134	116	107	74	67	67	68
Telecommunications	89	91	110	120	134	142	136	133
Utilities	75	81	98	104	183	161	148	139
Banks	130	94	83	77	97	106	114	132
Insurance	80	71	74	76	112	116	115	109
Real Estate	142	138	147	154	119	118	116	109
Financial Services	126	97	107	107	105	99	101	99
Technology	235	193	133	129	58	46	47	46
Stoxx - Pan Europe	100	100	100	100	100	100	100	100
Pan Euro - Large Cap	94	95	97	98	103	104	104	104
Pan Euro - Mid Cap	127	123	115	111	89	83	85	85
Pan Euro - Small Cap	189	133	119	112	87	83	85	84
Stoxx ex UK - Europe ex UK	108	104	101	100	97	98	98	98
Stoxx Eurozone - Eurozone	106	102	98	97	99	99	97	98

Source: Citi Research & DataStream

Figure 45. Pan-European Sector Growth

Sector	Earnings Growth %			Net Dividend Growth %		
	2013E	2014E	2015E	2013E	2014E	2015E
Oil & Gas	-12.2	12.6	2.9	1.4	2.6	5.3
Chemicals	-0.9	5.9	13.8	1.5	7.2	9.3
Basic Resources	-3.4	16.1	19.5	-7.1	2.9	6.5
Construction & Materials	-4.7	19.8	16.8	4.5	7.4	8.4
Industrial Goods & Services	-0.3	14.7	11.7	5.6	8.0	9.7
Automobiles & Parts	-10.8	14.0	17.4	3.5	10.7	12.3
Food & Beverage	1.9	6.5	9.2	6.2	8.4	7.8
Personal & H'hold Goods	4.6	9.5	10.7	8.8	6.8	11.7
Health Care	-3.9	9.7	9.8	2.0	7.5	8.2
Retail	1.0	9.7	9.0	0.4	6.5	8.1
Media	-7.1	9.8	9.9	-9.6	5.8	5.8
Travel & Leisure	8.6	30.5	20.3	-6.8	7.1	12.7
Telecommunications	1.8	-7.3	2.0	8.9	2.7	8.6
Utilities	-4.6	-7.3	5.0	-9.8	-1.3	3.6
Banks	44.0	27.0	19.2	12.3	15.6	27.6
Insurance	16.6	7.9	7.5	5.8	6.2	5.5
Real Estate	6.7	5.1	6.3	2.3	5.3	4.0
Financial Services	34.9	1.5	11.5	-3.5	8.6	8.8
Technology	26.5	63.5	14.1	-18.6	8.5	10.0
Stoxx - Pan Europe	3.9	12.1	11.2	2.8	7.0	10.7
Pan Euro - Large Cap	1.9	10.5	10.3	4.1	6.5	10.9
Pan Euro - Mid Cap	7.4	19.9	14.8	-4.4	9.5	10.3
Pan Euro - Small Cap	48.4	25.0	18.1	-2.3	9.3	9.4
Stoxx ex UK - Europe ex UK	7.4	15.5	12.8	3.0	7.1	11.6
Stoxx Eurozone - Eurozone	7.5	16.4	13.0	2.3	5.4	11.8

Source: Citi Research & DataStream

Figure 46. Pan-European Sector Ratings

Sector	Price/Earnings				Net Dividend Yield			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Oil & Gas	9.8	11.1	9.9	9.6	4.38	4.44	4.55	4.79
Chemicals	16.0	16.2	15.3	13.4	2.64	2.68	2.87	3.14
Basic Resources	13.5	14.0	12.0	10.1	3.53	3.28	3.37	3.59
Construction & Materials	16.7	17.5	14.6	12.5	3.03	3.17	3.40	3.69
Industrial Goods & Services	16.8	16.9	14.7	13.2	2.65	2.79	3.02	3.31
Automobiles & Parts	9.4	10.5	9.2	7.8	2.86	2.96	3.27	3.67
Food & Beverage	19.6	19.2	18.0	16.5	2.67	2.84	3.08	3.32
Personal & H'hold Goods	18.5	17.7	16.2	14.6	2.52	2.74	2.92	3.26
Health Care	15.2	15.8	14.4	13.1	3.11	3.17	3.40	3.68
Retail	18.1	17.9	16.3	14.9	2.87	2.88	3.07	3.32
Media	16.2	17.4	15.9	14.4	3.71	3.35	3.55	3.76
Travel & Leisure	21.6	19.9	15.2	12.7	2.42	2.25	2.41	2.72
Telecommunications	13.7	13.4	14.5	14.2	4.38	4.77	4.90	5.32
Utilities	11.5	12.0	13.0	12.3	6.00	5.41	5.34	5.53
Banks	19.9	13.8	10.9	9.1	3.17	3.56	4.11	5.25
Insurance	12.2	10.5	9.7	9.0	3.68	3.90	4.14	4.37
Real Estate	21.8	20.4	19.4	18.2	3.88	3.97	4.18	4.35
Financial Services	19.3	14.3	14.1	12.7	3.46	3.33	3.62	3.94
Technology	36.1	28.6	17.5	15.3	1.90	1.55	1.68	1.84
Stoxx - Pan Europe	15.4	14.8	13.2	11.9	3.28	3.37	3.60	3.99
Pan Euro - Large Cap	14.4	14.1	12.8	11.6	3.36	3.50	3.73	4.13
Pan Euro - Mid Cap	19.5	18.1	15.1	13.2	2.92	2.79	3.06	3.37
Pan Euro - Small Cap	29.1	19.6	15.7	13.3	2.86	2.80	3.06	3.34
Stoxx ex UK - Europe ex UK	16.6	15.4	13.4	11.8	3.19	3.28	3.52	3.92
Stoxx Eurozone - Eurozone	16.2	15.1	13.0	11.5	3.25	3.32	3.51	3.92

Source: Citi Research & DataStream

Figure 47. Pan-European Country Weightings & Returns

	Mkt Cap (Euros m)	% of Stoxx	Relative Return to Stoxx				Absolute Return			
			1m	3m	12m	YTD	1m	3m	12m	YTD
Austria	25,043	0.4	0	5	1	-5	4	12	23	12
Belgium	102,563	1.6	-1	2	1	1	3	10	23	19
Denmark	128,427	2.0	1	0	-3	-1	5	8	18	16
Finland	96,945	1.5	2	14	21	16	6	23	47	37
France	1,000,453	15.2	0	0	5	2	3	7	27	21
Germany	871,937	13.3	1	1	3	1	5	9	25	19
Greece	8,173	0.1	11	31	41	32	15	41	71	55
Ireland	50,349	0.8	2	5	9	11	5	13	33	30
Italy	246,588	3.7	7	9	1	0	10	17	23	18
Netherlands	265,135	4.0	0	-1	5	4	4	6	27	22
Norway	89,022	1.4	4	0	-10	-7	7	7	10	9
Portugal	19,725	0.3	-2	-3	-6	-7	2	4	15	10
Spain	323,944	4.9	4	9	7	5	7	17	30	24
Sweden	311,975	4.7	-3	-5	2	0	1	2	23	17
Switzerland	880,704	13.4	-2	-2	3	3	2	5	25	21
UK	2,159,390	32.8	-1	-2	-7	-5	3	6	13	12
Stoxx - Pan Europe	6,580,373	100								

Source: Citi Research & DataStream

Figure 48. Pan-European Country Relative Ratings

Country	Price/Earnings				Net Dividend Yield			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Austria	99	117	85	85	81	91	103	103
Belgium	119	117	122	121	100	93	104	102
Denmark	164	128	119	113	51	59	68	74
Finland	170	129	109	118	130	101	97	91
France	112	101	96	95	98	102	104	103
Germany	81	89	92	91	94	85	86	87
Greece	51	130	138	122	90	20	86	131
Ireland	141	165	131	120	46	48	48	46
Italy	116	112	99	95	97	97	98	101
Netherlands	110	109	101	100	75	71	73	70
Norway	80	86	83	85	137	134	135	137
Portugal	2040	265	112	91	129	101	104	107
Spain	137	108	109	105	136	160	133	142
Sweden	104	111	109	109	106	113	114	112
Switzerland	117	111	110	109	90	90	93	93
UK	87	92	98	100	106	105	105	103
EuroStoxx - Eurozone	106	102	98	97	99	99	97	98
Stoxx ex UK - Europe ex UK	108	104	101	100	97	98	98	98
Stoxx - Pan Europe	100	100	100	100	100	100	100	100

Source: Citi Research & DataStream

Figure 49. Pan-European Country Growth

Country	Earnings Growth %			Dividend Growth %		
	2013E	2014E	2015E	2013E	2014E	2015E
Austria	-12.4	54.7	11.0	15.7	20.4	11.1
Belgium	6.1	7.1	11.8	-3.6	19.2	8.5
Denmark	32.8	21.1	16.8	19.5	23.4	19.9
Finland	36.9	32.1	3.1	-20.1	2.9	3.3
France	15.0	18.4	12.3	7.6	8.9	9.8
Germany	-5.9	7.9	12.6	-6.7	7.5	12.9
Greece	-59.3	5.6	25.9	-77.5	366.4	68.5
Ireland	-11.2	41.6	20.9	7.9	6.8	5.7
Italy	7.4	27.1	15.8	2.7	8.2	14.5
Netherlands	4.1	21.8	12.0	-3.7	11.2	5.8
Norway	-2.4	15.1	9.0	0.6	8.3	12.2
Portugal	699.1	166.5	35.7	-20.2	10.8	14.2
Spain	32.6	10.8	15.1	21.0	-11.5	18.4
Sweden	-2.3	13.8	10.9	8.9	8.3	9.1
Switzerland	9.9	12.5	12.8	2.5	11.2	10.9
UK	-1.9	6.0	8.0	2.4	6.8	9.1
EuroStoxx - Eurozone	7.5	16.4	13.0	2.3	5.4	11.8
Stoxx ex UK - Europe ex UK	7.4	15.5	12.8	3.0	7.1	11.6
Stoxx - Pan Europe	3.9	12.1	11.2	2.8	7.0	10.7

Source: Citi Research & DataStream

Figure 50. Pan-European Country Ratings

Country	Price/Earnings				Net Dividend Yield			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Austria	15.2	17.3	11.2	10.1	2.66	3.08	3.71	4.12
Belgium	18.3	17.2	16.1	14.4	3.26	3.14	3.75	4.07
Denmark	25.2	19.0	15.7	13.4	1.66	1.99	2.45	2.94
Finland	26.1	19.1	14.4	14.0	4.25	3.40	3.50	3.61
France	17.2	15.0	12.6	11.3	3.20	3.44	3.75	4.12
Germany	12.4	13.2	12.2	10.8	3.08	2.87	3.08	3.48
Greece	7.9	19.3	18.2	14.5	2.96	0.67	3.11	5.24
Ireland	21.7	24.4	17.3	14.3	1.49	1.61	1.72	1.82
Italy	17.8	16.5	13.0	11.2	3.17	3.25	3.52	4.03
Netherlands	16.8	16.2	13.3	11.8	2.47	2.38	2.65	2.80
Norway	12.4	12.7	11.0	10.1	4.48	4.50	4.88	5.47
Portugal	313.3	39.2	14.7	10.8	4.24	3.39	3.75	4.29
Spain	21.1	15.9	14.4	12.5	4.46	5.40	4.78	5.66
Sweden	16.0	16.4	14.4	13.0	3.48	3.79	4.11	4.48
Switzerland	18.0	16.3	14.5	12.9	2.94	3.01	3.35	3.72
UK	13.4	13.6	12.9	11.9	3.46	3.54	3.78	4.12
EuroStoxx - Eurozone	16.2	15.1	13.0	11.5	3.25	3.32	3.51	3.92
Stoxx ex UK - Europe ex UK	16.6	15.4	13.4	11.8	3.19	3.28	3.52	3.92
Stoxx - Pan Europe	15.4	14.8	13.2	11.9	3.28	3.37	3.60	3.99

Source: Citi Research & DataStream

Figure 51. UK Sector Weightings & Relative Returns

As at Close 29 Oct 2013	Mkt Cap £m	% of AllShare	% of Group	Relative return				
				1m	3m	12m	Qtd	Ytd
OIL & GAS (26)	303,330	14.4		2	-3	-13	2	-8
Oil & Gas Producers (18)	290,671	13.8	96	2	-3	-13	2	-8
Oil Equip. Serv and Distrib (7)	12,567	0.6	4	1	1	-12	1	-8
BASIC MATERIALS (36)	170,869	8.1		-2	5	-21	-1	-23
Chemicals (8)	14,984	0.7	9	-1	3	1	-2	-4
Forestry & Paper (1)	4,065	0.2	2	1	16	38	1	41
Industrial Metals & Mining (4)	1,012	0.0	1	-6	8	-55	-6	-57
Mining (23)	150,808	7.2	88	-2	5	-23	-1	-25
INDUSTRIALS (110)	207,092	9.8		-1	1	9	-1	8
Construction & Materials (12)	17,317	0.8	8	-1	9	11	-1	7
Aerospace (9)	48,334	2.3	23	-3	-4	14	-2	14
General Industrials (6)	14,812	0.7	7	3	8	12	2	9
Electronic & Electrical Equip (13)	9,929	0.5	5	-2	2	7	-3	-2
Industrial Engineering (12)	21,463	1.0	10	-2	7	17	-2	10
Industrial Transportation (7)	3,094	0.1	1	3	12	30	3	28
Support Services (51)	92,143	4.4	44	-1	0	4	-1	6
CONSUMER GOODS (38)	287,013	13.6		0	-1	0	0	-1
Automobiles & Parts (1)	5,919	0.3	2	-1	7	47	1	35
Beverages (5)	87,583	4.2	31	-1	0	-2	-1	-3
Food Producers (11)	45,442	2.2	16	2	-4	-1	2	-3
Household Goods & Home Const (13)	49,863	2.4	17	6	2	17	4	15
Leisure Goods (2)	552	0.0	0	4	16	96	2	59
Personal Goods (4)	8,743	0.4	3	-10	-4	9	-11	5
Tobacco (2)	88,911	4.2	31	0	-2	-9	0	-7
HEALTH CARE (14)	150,899	7.2		1	-3	1	0	5
Health Care Equip & Services (6)	8,720	0.4	6	-1	-1	1	-1	-1
Pharmaceuticals & Biotech (8)	142,178	6.8	94	1	-3	1	0	6
CONSUMER SERVICES (84)	221,944	10.6		0	1	13	-1	10
Food & Drug Retailers (7)	46,633	2.2	21	-1	0	1	-1	0
General Retailers (22)	40,343	1.9	18	-3	-1	16	-4	15
Media (23)	67,119	3.2	30	2	5	20	1	15
Travel & Leisure (32)	67,850	3.2	31	0	-3	15	-1	10
TELECOMMUNICATIONS (8)	146,650	7.0		1	10	19	1	27
Fixed-Line Telecoms (6)	33,310	1.6	23	3	7	40	4	32
Mobile Telecoms (2)	113,341	5.4	77	0	11	15	0	26
UTILITIES (7)	76,380	3.6		-2	-5	-8	-2	-5
Electricity (2)	16,503	0.8	22	-6	-9	-12	-7	-8
Gas, Water & Multi-Utilities (5)	59,877	2.8	78	-1	-3	-6	-1	-4
TECHNOLOGY (23)	32,012	1.5		-5	1	8	-4	3
Software & Computer Serv (14)	14,026	0.7	44	-4	-6	4	-4	1
Technology Hardware & Equip (9)	17,986	0.9	56	-5	8	11	-4	4
TOTAL NON-FINANCIAL (346)	1,596,189	75.9		0	0	-2	0	0
FINANCIALS (265)	506,529	24.1		0	-1	6	0	2
Banks (6)	247,060	11.7	49	-2	-5	1	-2	-5
Non-Life Insurance (11)	20,550	1.0	4	0	-2	1	0	-2
Life Insurance (11)	86,816	4.1	17	5	7	23	5	16
Real Estate Inv. Servs (22)	10,264	0.5	2	2	2	23	1	19
REITS (16)	31,856	1.5	6	4	3	2	4	1
Financial Services (26)	42,159	2.0	8	2	3	21	2	17
FTSE ALL SHARE (611)	2,102,718	100.0		0	0	0	0	0
FTSE 100 (100)	1,747,691	83.1		0	0	-2	0	-1
Mid 250 (250)	299,155	14		0	1	9	0	7
Small Cap (261)	55,872	3		-1	4	11	-1	9

Source: Citi Research & DataStream

Figure 52. UK Relative Ratings

As at Close 29 Oct 2013	P/E Relative				Yield Relative			
	2012E	2013E	2014E	2015E	2012E	2013E	2014E	2015E
OIL & GAS	70	78	75	80	118	120	113	106
Oil & Gas Producers	69	78	75	79	120	122	114	107
Oil Equip. Serv and Distrib	109	96	91	89	74	75	83	84
BASIC MATERIALS	86	96	94	83	96	92	89	88
Chemicals	133	132	131	129	64	65	65	67
Forestry & Paper	141	102	95	102	63	67	87	81
Industrial Metals & Mining	-48	-189	-	85	36	17	27	50
Mining	81	92	91	80	101	96	92	90
INDUSTRIALS	123	120	117	114	77	75	73	72
Construction & Materials	128	167	132	113	105	103	99	95
Aerospace	108	98	101	101	81	81	80	78
General Industrials	110	107	102	102	82	82	85	83
Electronic & Electrical Equip	129	125	123	122	60	61	61	61
Industrial Engineering	138	129	126	126	61	61	61	60
Industrial Transportation	128	122	119	119	73	74	71	69
Support Services	129	127	124	121	75	71	67	68
CONSUMER GOODS	131	125	125	123	85	90	88	90
Automobiles & Parts	99	94	87	84	61	66	70	74
Beverages	154	148	149	147	62	65	66	66
Food Producers	141	135	136	134	85	87	85	85
Household Goods & Home Const	141	130	125	122	64	80	75	84
Personal Goods	166	148	140	138	53	57	61	63
Tobacco	107	104	106	105	125	125	123	123
HEALTH CARE	88	99	105	108	123	122	117	112
Health Care Equip & Services	119	122	122	119	61	58	57	58
Pharmaceuticals & Biotech	87	98	104	108	127	126	121	115
CONSUMER SERVICES	119	115	111	111	83	82	80	78
Food & Drug Retailers	88	95	102	109	114	110	103	96
General Retailers	127	118	114	111	71	72	72	71
Media	123	119	116	114	76	82	81	82
Travel & Leisure	142	125	112	109	77	69	68	67
TELECOMMUNICATIONS	107	107	129	138	133	125	124	126
Fixed-Line Telecoms	111	111	104	98	82	86	91	116
Mobile Telecoms	105	106	139	157	148	137	134	129
UTILITIES	103	105	106	108	151	146	142	137
Electricity	89	97	96	94	166	153	148	147
Gas, Water & Multi-Utilities	107	108	109	112	146	144	140	134
TECHNOLOGY	198	187	173	161	36	40	43	46
Software & Computer Serv	138	138	134	129	56	58	59	59
Technology Hardware & Equip	299	259	223	201	21	26	31	36
TOTAL NON-FINANCIAL	99	104	104	104	102	101	98	96
FINANCIALS	103	89	89	88	94	97	109	116
Banks	96	80	79	78	85	94	114	128
Non-Life Insurance	84	78	81	83	166	138	135	130
Life Insurance	95	96	95	96	102	102	103	102
Real Estate Inv. Servs	234	206	198	191	60	61	60	58
REITS	189	190	190	190	100	98	94	90
Financial Services	130	92	98	96	103	92	97	98
FTSE ALL SHARE	100	100	100	100	100	100	100	100
FTSE 100	97	98	98	98	104	104	104	104
Mid 250	119	117	117	112	79	74	76	76
Small Cap	148	128	114	99	69	67	67	66

Source: Citi Research & DataStream

Figure 53. UK Sector Growth

As at Close 29 Oct 2013	Earnings Growth %			Net Dividend Growth %		
	2013E	2014E	2015E	2013E	2014E	2015E
OIL & GAS	-9.1	11.4	2.1	8.1	0.7	2.5
Oil & Gas Producers	-9.8	11.3	1.8	8.1	0.3	2.2
Oil Equip, Serv. and Distrib	15.9	13.5	10.8	8.0	18.9	10.5
BASIC MATERIALS	-8.7	9.6	21.6	1.6	4.2	7.5
Chemicals	2.8	7.8	9.7	8.3	7.9	11.9
Forestry & Paper	40.0	15.0	1.1	13.4	40.4	1.1
Industrial Metals & Mining	-74.0	-	-	-49.2	71.9	101.7
Mining	-10.9	9.0	22.4	1.1	3.2	7.2
INDUSTRIALS	4.5	9.7	11.1	4.1	4.3	8.0
Construction & Materials	-22.0	35.2	27.3	4.6	2.8	4.8
Aerospace	11.9	3.9	8.4	6.3	6.3	6.5
General Industrials	4.6	11.7	8.6	6.9	10.6	7.2
Electronic & Electrical Equip	4.8	8.8	9.4	8.1	8.1	8.6
Industrial Engineering	9.2	10.3	7.8	6.6	7.0	6.8
Industrial Transportation	6.9	9.6	8.2	6.9	3.7	5.5
Support Services	3.8	9.7	11.4	1.3	1.6	10.3
CONSUMER GOODS	7.0	7.0	9.6	11.6	5.6	11.4
Automobiles & Parts	7.8	15.1	12.0	15.0	15.0	15.0
Beverages	6.2	6.3	9.8	10.9	8.6	10.1
Food Producers	6.2	6.8	9.5	9.3	4.9	8.8
Household Goods & Home Cor	10.7	10.9	11.2	33.6	1.0	21.9
Personal Goods	14.2	13.6	9.3	14.2	13.9	12.5
Tobacco	5.8	4.9	8.6	6.4	5.2	9.4
HEALTH CARE	-9.0	1.2	4.5	5.0	3.5	4.2
Health Care Equip & Services	-0.1	6.9	10.7	0.8	6.3	9.9
Pharmaceuticals & Biotech	-9.4	1.0	4.2	5.1	3.4	4.0
CONSUMER SERVICES	5.7	10.4	8.5	4.6	4.6	6.6
Food & Drug Retailers	-5.4	0.2	1.1	1.8	1.2	1.0
General Retailers	9.5	11.3	10.5	7.9	7.3	8.6
Media	5.7	9.6	10.5	15.3	5.8	9.7
Travel & Leisure	15.5	19.8	11.0	-4.6	5.2	7.5
TELECOMMUNICATIONS	1.5	-11.2	1.3	0.0	6.9	10.6
Fixed-Line Telecoms	2.1	14.2	14.5	11.5	13.6	38.7
Mobile Telecoms	1.4	-18.3	-3.9	-1.9	5.6	5.0
UTILITIES	-0.6	6.4	6.5	3.1	4.6	5.3
Electricity	-6.4	8.0	10.9	-2.2	4.3	8.1
Gas, Water & Multi-Utilities	1.3	5.9	5.1	4.7	4.7	4.5
TECHNOLOGY	7.6	16.2	15.9	15.8	17.3	16.3
Software & Computer Serv	1.6	10.4	12.6	9.2	10.6	9.2
Technology Hardware & Equip	17.7	24.6	20.1	29.3	29.0	26.9
TOTAL NON-FINANCIAL	-2.2	7.0	7.9	5.6	4.0	6.9
FINANCIALS	17.4	7.7	9.1	9.3	20.5	16.0
Banks	21.9	8.6	10.0	18.0	30.6	21.9
Non-Life Insurance	10.3	3.3	4.8	-11.5	5.1	5.1
Life Insurance	0.3	9.0	7.0	5.7	9.1	8.1
Real Estate Inv. Servs	15.7	11.5	12.3	7.8	7.2	4.7
REITS	1.1	7.1	8.1	3.9	3.6	4.5
Financial Services	43.8	1.2	10.5	-4.9	13.2	9.8
FTSE ALL SHARE	1.9	7.2	8.2	6.3	7.5	9.0
FTSE 100	1.5	7.0	7.5	7.0	7.3	9.1
Mid 250	3.8	7.2	12.3	0.3	9.8	8.9
Small Cap	17.3	20.9	25.0	2.3	7.8	7.9

Source: Citi Research & DataStream

Figure 54. UK Sector Ratings

As at Close 29 Oct 2013	Price/Earnings				Net Dividend Yield			
	2012E	2013E	2014E	2015E	2012E	2013E	2014E	2015E
OIL & GAS	9.8	10.8	9.7	9.5	3.86	4.18	4.21	4.31
Oil & Gas Producers	9.6	10.7	9.6	9.4	3.92	4.24	4.26	4.35
Oil Equip, Serv and Distrib	15.3	13.2	11.6	10.5	2.40	2.60	3.09	3.41
BASIC MATERIALS	12.0	13.2	12.0	9.9	3.15	3.20	3.33	3.58
Chemicals	18.6	18.1	16.8	15.3	2.09	2.26	2.44	2.73
Forestry & Paper	19.7	14.1	12.2	12.1	2.05	2.33	3.27	3.30
Industrial Metals & Mining	-6.8	-26.0	-	10.1	1.16	0.59	1.01	2.05
Mining	11.3	12.7	11.6	9.5	3.30	3.33	3.44	3.69
INDUSTRIALS	17.2	16.4	15.0	13.5	2.52	2.62	2.73	2.95
Construction & Materials	17.9	22.9	17.0	13.3	3.43	3.59	3.69	3.86
Aerospace	15.1	13.5	13.0	12.0	2.64	2.80	2.98	3.18
General Industrials	15.3	14.7	13.1	12.1	2.68	2.86	3.16	3.39
Electronic & Electrical Equip	18.0	17.2	15.8	14.5	1.95	2.11	2.28	2.48
Industrial Engineering	19.4	17.8	16.1	14.9	1.99	2.12	2.27	2.43
Industrial Transportation	17.9	16.7	15.3	14.1	2.39	2.56	2.65	2.80
Support Services	18.1	17.5	15.9	14.3	2.44	2.48	2.51	2.77
CONSUMER GOODS	18.3	17.1	16.0	14.6	2.79	3.12	3.29	3.67
Automobiles & Parts	13.9	12.9	11.2	10.0	1.98	2.28	2.62	3.01
Beverages	21.5	20.3	19.1	17.4	2.04	2.26	2.45	2.70
Food Producers	19.7	18.6	17.4	15.9	2.77	3.03	3.18	3.46
Household Goods & Home Co	19.8	17.8	16.1	14.5	2.08	2.78	2.80	3.42
Personal Goods	23.2	20.3	17.9	16.4	1.74	1.99	2.27	2.55
Tobacco	15.0	14.2	13.6	12.5	4.10	4.36	4.58	5.01
HEALTH CARE	12.4	13.6	13.4	12.8	4.03	4.23	4.38	4.56
Health Care Equip & Services	16.7	16.7	15.6	14.1	2.00	2.01	2.14	2.35
Pharmaceuticals & Biotech	12.2	13.4	13.3	12.8	4.15	4.36	4.51	4.69
CONSUMER SERVICES	16.6	15.7	14.3	13.1	2.73	2.86	2.99	3.19
Food & Drug Retailers	12.4	13.1	13.1	12.9	3.74	3.81	3.86	3.90
General Retailers	17.8	16.2	14.6	13.2	2.31	2.49	2.67	2.90
Media	17.2	16.3	14.9	13.5	2.48	2.86	3.03	3.32
Travel & Leisure	19.9	17.2	14.4	13.0	2.53	2.41	2.54	2.73
TELECOMMUNICATIONS	14.9	14.7	16.6	16.3	4.35	4.35	4.65	5.14
Fixed-Line Telecoms	15.5	15.2	13.3	11.6	2.68	2.99	3.40	4.71
Mobile Telecoms	14.8	14.6	17.8	18.5	4.84	4.75	5.02	5.27
UTILITIES	14.4	14.5	13.6	12.8	4.92	5.07	5.31	5.59
Electricity	12.5	13.4	12.4	11.1	5.44	5.32	5.55	5.99
Gas, Water & Multi-Utilities	15.0	14.8	14.0	13.3	4.78	5.01	5.24	5.48
TECHNOLOGY	27.7	25.8	22.2	19.1	1.19	1.38	1.62	1.88
Software & Computer Serv	19.3	19.0	17.2	15.3	1.83	2.00	2.21	2.42
Technology Hardware & Equip	41.9	35.6	28.6	23.8	0.69	0.90	1.16	1.47
TOTAL NON-FINANCIAL	13.9	14.2	13.3	12.3	3.32	3.50	3.65	3.90
FINANCIALS	14.4	12.2	11.4	10.4	3.09	3.37	4.07	4.72
Banks	13.4	11.0	10.1	9.2	2.77	3.27	4.27	5.20
Non-Life Insurance	11.8	10.7	10.3	9.9	5.42	4.80	5.04	5.29
Life Insurance	13.3	13.2	12.2	11.4	3.35	3.54	3.86	4.17
Real Estate Inv. Servs	32.8	28.3	25.4	22.6	1.95	2.10	2.26	2.36
REITS	26.4	26.1	24.4	22.6	3.27	3.39	3.52	3.67
Financial Services	18.3	12.7	12.6	11.4	3.38	3.21	3.63	3.99
FTSE ALL SHARE	14.0	13.7	12.8	11.8	3.27	3.48	3.74	4.07
FTSE 100	13.6	13.4	12.5	11.7	3.39	3.62	3.89	4.24
Mid 250	16.7	16.0	15.0	13.3	2.57	2.58	2.84	3.09
Small Cap	20.7	17.7	14.6	11.7	2.27	2.32	2.50	2.70

Source: Citi Research & DataStream

Figure 55. Stocks Mentioned In The Report

Stock Name	RIC	Price	Rating	Currency	Stock Name	RIC	Price	Rating	Currency
ABB	ABBN.VX	23.13	2	CHF	Kingfisher	KGF.L	3.79	1	GBP
Aberdeen Asset Man.	ADN.L	4.45	2	GBP	Kuehne+Nagel Intl.	KNIN.VX	114.90	1	CHF
ABInbev	ABI.BR	75.89	1	EUR	Legal & General	LGEN.L	2.18	2	GBP
Actelion	ATLN.VX	70.00	2	CHF	Legrand	LEGD.PA	42.10	2	EUR
Adecco R	ADEN.VX	66.25	3	CHF	Lloyds Banking Group	LLOY.L	0.78	2	GBP
Admiral Group	ADML.L	12.74	2	GBP	LVMH	LVMH.PA	141.85	1	EUR
Aegon	AEGN.AS	5.86	2	EUR	Marks & Spencer Group	MKS.L	4.92	1	GBP
Aggreko	AGGK.L	16.02	1	GBP	Melrose Industries	MRON.L	3.21	2	GBP
Ahold Kon.	AHLN.AS	14.03	1	EUR	Merck KGAA	MRCG.DE	122.70	2	EUR
Air Liquide	AIRP.PA	99.99	2	EUR	Michelin	MICP.PA	77.36	1	EUR
Alfa Laval	ALFA.ST	148.80	2	SEK	Mondi	MNDI.L	11.16	2	GBP
Allianz	ALVG.DE	123.25	1	EUR	Nestle R	NESN.VX	65.35	1	CHF
ASML Hldg	ASML.AS	69.55	1	EUR	Next	NXT.L	54.13	1	GBP
Assa Abloy B	ASSAb.ST	317.10	3	SEK	Nokia	NOK1V.HE	5.59	2H	EUR
Assicurazioni Generali	GASI.MI	17.09	3	EUR	Nordea Bank	NDA.ST	83.90	1	SEK
AstraZeneca	AZN.L	32.86	2	GBP	Novartis R	NOVN.VX	70.50	1	CHF
Atlas Copco A	ATCOa.ST	181.30	3	SEK	Novo Nordisk B	NOVOb.CO	987.00	1	DKK
Aviva	AV.L	4.51	1	GBP	Pernod-Ricard	PERP.PA	88.74	2	EUR
AXA	AXAF.PA	18.27	1	EUR	Philips Electronics	PHG.AS	26.02	1	EUR
Barclays	BARC.L	2.68	1	GBP	Prudential	PRU.L	12.80	1	GBP
Bayer	BAYGn.DE	91.52	1	EUR	Randgold Resources	RRS.L	46.63	3	GBP
Beiersdorf	BEIG.DE	70.59	1	EUR	RBS	RBS.L	3.67	3H	GBP
BHP Billiton	BLT.L	19.48	2	GBP	Reckitt Benckiser Group	RB.L	48.34	1	GBP
BMW	BMWG.DE	83.19	2	EUR	Renault	RENA.PA	65.64	1	EUR
BNP Paribas	BNPP.PA	54.37	1	EUR	Resolution	RSL.L	3.57	2	GBP
BP	BP.L	4.85	2	GBP	Richemont N	CFR.VX	92.40	1	CHF
Brenntag	BNRGn.DE	124.55		EUR	Rio Tinto	RIO.L	32.01	1	GBP
British American Tobacco	BATS.L	34.59	1	GBP	Roche	ROG.VX	250.70	1	CHF
BSkyB	BSY.L	9.35	1	GBP	Royal Dutch Shell A	RDSa.L	20.83	2	GBP
Burberry Group	BRBY.L	15.38	2	GBP	Ryanair Holdings	RYA.I	6.12	1	EUR
Cap Gemini	CAPP.PA	48.66	1	EUR	Sanofi	SASY.PA	78.60	1	EUR
Christian Dior	DIOR.PA	139.95		EUR	SAP	SAPG.DE	57.70	2	EUR
Coloplast 'B'	COLOb.CO	325.40	1	DKK	Schneider Electric	SCHN.PA	61.81	2	EUR
Continental	CONG.DE	134.85	1	EUR	Seadrill	SDRL.OL	275.80	1	NOK
Credit Agricole	CAGR.PA	8.89	1	EUR	SEB A	SEBa.ST	78.45	1	SEK
Credit Suisse R	CSGN.VX	28.37	1	CHF	SGS N	SGSN.VX	2117.00	1	CHF
Daimler	DAIGn.DE	60.22	2	EUR	Shire	SHP.L	27.70	1	GBP
Danone	DANO.PA	54.69	2	EUR	Siemens	SIEGn.DE	93.58	1	EUR
Danske Bank	DANSKE.CO	125.70	1	DKK	Skanska B	SKAb.ST	125.00		SEK
Dassault Systemes	DAST.PA	88.94	1	EUR	Smith & Nephew	SN.L	7.94	2	GBP
Deutsche Boerse	DB1Gn.DE	55.30	2	EUR	Smiths Group	SMIN.L	14.21	3	GBP
Deutsche Telekom	DTEGn.DE	11.53	2	EUR	Societe Generale	SOGN.PA	41.78	1	EUR
DNB	DNB.OL	105.50	2	NOK	Sodexo	EXHO.PA	71.56	1	EUR
EADS	EAD.PA	49.97	1	EUR	SSE	SSE.L	14.15	3	GBP
ENI	ENI.MI	18.21	2	EUR	Standard Ch	STAN.L	15.11	1	GBP
Essilor Intl.	ESSI.PA	79.66	1	EUR	Standard Life	SL.L	3.53	2	GBP
GBL	GBLB.BR	65.57		EUR	Svenska Handbkn	SHBa.ST	295.60	2	SEK
Geberit R	GEBN.VX	264.90	3	CHF	Swatch B	UHR.VX	580.50	2	CHF
GKN	GKN.L	3.67	1	GBP	Syngenta	SYNN.VX	366.80	2	CHF
Hargreaves Lansdown	HRGV.L	11.91	3	GBP	Tate & Lyle	TATE.L	7.89	1	GBP
HeidelbergCement	HEIG.DE	57.91	1	EUR	Telefonica	TEF.MC	12.90	2	EUR
Henkel Pref.	HNKG_p.DE	79.54	2	EUR	Total	TOTF.PA	45.06	2	EUR
HSBC Holdings	HSBA.L	6.84	1	GBP	Tullow Oil	TLW.L	9.49	2	GBP
IAG	ICAG.L	3.53	1	GBP	UBS	UBSN.VX	17.59	1	CHF
IMI	IMI.L	15.28	1	GBP	Unilever (UK)	ULVR.L	25.24	2	GBP
ING Groep	ING.AS	9.38	1	EUR	Unilever Certs.	UNc.AS	29.15	2	EUR
Intertek Group	ITRK.L	33.50	1	GBP	Valeo	VLOF.PA	73.42	1	EUR
Intesa Sanpaolo	ISP.MI	1.82	3H	EUR	Weir Group	WEIR.L	22.86	2	GBP
ITV	ITV.L	1.92	1	GBP	William Hill	WMH.L	4.01	1	GBP
KBC Groupe	KBC.BR	39.96	1	EUR	WPP	WPP.L	13.22	2	GBP
Kering	PRTP.PA	167.75	1	EUR	Yara International	YAR.OL	257.50	1	NOK

Source: Citi Research. *Prices as of 30th October 2013

Notes

Notes

Notes

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

An employee of Citigroup Global Markets or its affiliates is chairman of the audit committee and Non-Executive Director of Smiths Group.

Citigroup Global Markets Limited is currently acting as advisor to Assicurazioni Generali Spa (the company) in the announced sale of the company's US Life Reinsurance Business (Generali U.S.) to Scor SE

Citigroup Global Markets Limited acted as advisor to Telefonica SA in the announced acquisition of E-Plus Service GmbH & Co by Telefonica Deutschland GmbH & Co. from Koninklijke KPN NV

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Svenska Handelsbanken AB

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Royal Bank of Scotland Group PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Pernod Ricard SA

An employee of Citigroup Global Markets or its affiliates is the Non-Executive Chairman of the Legal & General Group PLC.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Skandinaviska Enskilda Banken AB

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Credit Agricole SA

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Sanofi SA

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Intesa Sanpaolo SpA

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Nordea Bank AB

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Danske Bank A/S.

Citigroup Global Markets Ltd acted a Joint Bookrunner and Lead Manager on Cap Gemini SA's announced convertible bond.

Interbank Offered Rates-Related Litigation and Other Matters: Government agencies in the U.S., including the Department of Justice, the Commodity Futures Trading Commission and the Securities and Exchange Commission, as well as agencies in other jurisdictions, including the European Commission, the U.K. Financial Services Authority, the Japanese Financial Services Agency (JFSA) and the Canadian Competition Bureau, are conducting investigations or making inquiries regarding submissions made by panel banks to bodies that publish various interbank offered rates. As members of a number of such panels, Citigroup subsidiaries have received requests for information and documents. Citigroup is cooperating with the investigations and inquiries and is responding to the requests. Consequently Citi Research is not commenting on the quantum or likelihood of any potential LIBOR related claims or settlements.

Citigroup Global Markets Ltd is currently acting as advisor to Allianz SE in relation to the recent announcement of Allianz SE's acquisition of Yapi Kredi Sigorta AS.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Koninklijke Philips NV

The Chairman of Citi serves as a director of Roche Holding AG.

Citigroup Global Markets Ltd is currently mandated as Joint Corporate Broker to IMI Plc, and has been mandated as Joint Financial Advisor to IMI Plc on the announced disposal of their Beverage Dispense and Merchandising divisions to The Marmon Group LLC and the proposed return of cash.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Standard Chartered PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of BNP Paribas SA Citigroup Global Markets Limited is currently mandated as sole global co-ordinator in relation to the recently announced re-IPO of BNP Paribas SA's polish subsidiary, BNP Paribas Bank Polska.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of HSBC Holdings PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Nokia Oyj

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Societe Generale

Citigroup Global Markets Limited acted as Lead Financial Advisor and Joint Broker to William Hill Plc in the recently completed acquisition of the Sportingbet Plc Australian Business and certain other assets from the Sportingbet Group, including a call option over the Sportingbet Plc Spanish Business. Citigroup Global Markets Limited is also acting as Financial Adviser, Sole Sponsor, Joint Global Coordinator and Joint Bookrunner in the announced rights offering for William Hill Plc.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Bp PLC.

Citigroup Global Markets Limited is currently mandated as advisor to Lloyds Banking Group Plc in relation to the announced disposal of the Groups UK bank branches.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Randgold Resources Ltd

An employee of Citigroup Global Markets or its affiliates is a Sales Consultant of Next Retail Ltd.

Thomas Dörner, Analyst, holds a long position in the securities of Resolution.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Nokia Oyj, Societe Generale. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Telefonica SA, Royal Bank of Scotland Group PLC, Skandinaviska Enskilda Banken AB, Novartis AG, Credit Agricole SA, Prudential Plc, Nestle, Sanofi SA, Intesa Sanpaolo, Aberdeen Asset Management, Aggreko PLC, Nordea, Danske Bank A/S, Siemens, Capgemini SA, Total, Barclays PLC, Continental AG, Allianz SE, Aegon NV, Credit Suisse, British American Tobacco PLC, Daimler AG, International Consolidated Airlines Group, S.A., Renault SA, BNP Paribas SA, Aviva PLC, ING Groep NV, BMW AG, Reckitt Benckiser, EADS, Nokia Oyj, Unilever PLC, Societe Generale, Danone, Resolution, AXA SA, William Hill, BP, Atlas Copco.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from WPP PLC, SAP AG, Deutsche Telekom AG, Smiths Group, Assicurazioni Generali SpA, Telefonica SA, Svenska Handelsbanken AB, Yara International, Royal Bank of Scotland Group PLC, Pernod-Ricard, Legal & General, Skandinaviska Enskilda Banken AB, Essilor, Novartis AG, AB-InBev, Credit Agricole SA, Prudential Plc, Bayer AG, Nestle, UBS, Sanofi SA, Intesa Sanpaolo, Aberdeen Asset Management, Sodexo, Valeo SA, Nordea, Rio Tinto PLC, Danske Bank A/S, Siemens, Capgemini SA, Total, Ryanair, Henkel, Barclays PLC, Continental AG, Allianz SE, Aegon NV, Michelin, Credit Suisse, Roche Holding AG, IMI, Tate and Lyle, Standard Life PLC, British American Tobacco PLC, HeidelbergCement AG, LVMH, Assa Abloy, L'Air Liquide SA, Standard Chartered PLC, Daimler AG, International Consolidated Airlines Group, S.A., Renault SA, BNP Paribas SA, Shire Pharmaceuticals, Aviva PLC, KBC, ING Groep NV, BMW AG, Unilever NV, Reckitt Benckiser, HSBC Holdings PLC, EADS, GKN Plc, DNB ASA, ABB, Nokia Oyj, Unilever PLC, Societe Generale, Seadrill, Danone, Resolution, AXA SA, William Hill, Marks and Spencer Group PLC, Eni, Mondi Plc, Merck KGaA, BP, BHP Billiton PLC, Lloyds Banking Group PLC, Deutsche Boerse AG, Atlas Copco, Syngenta AG, Royal Dutch Shell, ASML Holding NV.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from SAP AG, Assicurazioni Generali SpA, Telefonica SA, Royal Bank of Scotland Group PLC, Skandinaviska Enskilda Banken AB, AB-InBev, Nestle, UBS, Sanofi SA, Siemens, Henkel, Allianz SE, Aegon NV, IMI, Schneider Electric, L'Air Liquide SA, BNP Paribas SA, BMW AG, HSBC Holdings PLC, GKN Plc, Seadrill, Eni, BP, Lloyds Banking Group PLC.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from WPP PLC, SAP AG, Swatch Group AG, SSE PLC, Deutsche Telekom AG, Smiths Group, Assicurazioni Generali SpA, Telefonica SA, Svenska Handelsbanken AB, Yara International, Royal Bank of Scotland Group PLC, Pernod-Ricard, Legal & General, Skandinaviska Enskilda Banken AB, Richemont, Essilor, Novartis AG, AB-InBev, Credit Agricole SA, Adecco, Prudential Plc, Bayer AG, Nestle, UBS, Sanofi SA, Intesa Sanpaolo, Aberdeen Asset Management, Melrose, Sodexo, Aggreko PLC, Valeo SA, Nordea, Rio Tinto PLC, Danske Bank A/S, Siemens, Capgemini SA, Total, Ryanair, Henkel, Barclays PLC, Continental AG, Allianz SE, Legrand, Tullow Oil, Philips, Alfa Laval, Ahold, Aegon NV, Michelin, Beiersdorf, Credit Suisse, Roche Holding AG, IMI, Dassault Systemes SA, British Sky Broadcasting Group PLC, Tate and Lyle, Standard Life PLC, Schneider Electric, Admiral Group, ITV PLC, British American Tobacco PLC, AstraZeneca PLC, HeidelbergCement AG, LVMH, Assa Abloy, L'Air Liquide SA, Standard Chartered PLC, Daimler AG, International Consolidated Airlines Group, S.A., Renault SA, BNP Paribas SA, Shire Pharmaceuticals, Aviva PLC, KBC, ING Groep NV, BMW AG, Unilever NV, Reckitt Benckiser, Coloplast, HSBC Holdings PLC, EADS, Kering, GKN Plc, DNB ASA, ABB, Nokia Oyj, Unilever PLC, SGS, Societe Generale, Seadrill, Actelion Ltd, Danone, Resolution, Kuehne & Nagel International, AXA SA, William Hill, Marks and Spencer Group PLC, Eni, Mondi Plc, Merck KGaA, BP, BHP Billiton PLC, Lloyds Banking Group PLC, Intertek, Deutsche Boerse AG, Randgold Resources Ltd, Atlas Copco, Syngenta AG, Next Group PLC, Novo Nordisk A/S, Royal Dutch Shell in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): KBC, ING Groep NV, HSBC Holdings PLC, Roche Holding AG, Marks and Spencer Group PLC, Barclays PLC, Royal Bank of Scotland Group PLC, WPP PLC, SAP AG, Deutsche Telekom AG, Smiths Group, Assicurazioni Generali SpA, Telefonica SA, Svenska Handelsbanken AB, Yara International, Pernod-Ricard, Legal & General, Skandinaviska Enskilda Banken AB, Essilor, Novartis AG, AB-InBev, Credit Agricole SA, Prudential Plc, Bayer AG, Nestle, UBS, Sanofi SA, Intesa Sanpaolo, Aberdeen Asset Management, Sodexo, Valeo SA, Nordea, Rio Tinto PLC, Danske Bank A/S, Siemens, Capgemini SA, Total, Ryanair, Henkel, Continental AG, Allianz SE, Aegon NV, Michelin, Credit Suisse, IMI, Tate and Lyle, Standard Life PLC, Schneider Electric, British American Tobacco PLC, HeidelbergCement AG, LVMH, Assa Abloy, L'Air Liquide SA, Standard Chartered PLC, Daimler AG, International Consolidated Airlines Group, S.A., Renault SA, BNP Paribas SA, Shire Pharmaceuticals, Aviva PLC, BMW AG, Unilever NV, Reckitt Benckiser, EADS, GKN Plc, DNB ASA, ABB, Nokia Oyj, Unilever PLC, Societe Generale, Seadrill, Danone, Resolution, AXA SA, William Hill, Eni, Mondi Plc, Merck KGaA, BP, BHP Billiton PLC, Lloyds Banking Group PLC, Deutsche Boerse AG, Atlas Copco, Syngenta AG, Royal Dutch Shell, ASML Holding NV.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: ITV PLC, WPP PLC, Hargreaves Lansdown PLC, SAP AG, Swatch Group AG, SSE PLC, Deutsche Telekom AG, Smiths Group, Assicurazioni Generali SpA, Telefonica SA, Svenska Handelsbanken AB, Yara International, Royal Bank of Scotland Group PLC, Pernod-Ricard, Legal & General, Skandinaviska Enskilda Banken AB, Richemont, Essilor, Novartis AG, Burberry Group PLC, AB-InBev, Credit Agricole SA, Adecco, Prudential Plc, Bayer AG, Nestle, UBS, Sanofi SA, Intesa Sanpaolo, Aberdeen Asset Management, Melrose, Sodexo, Aggreko PLC, Valeo SA, Nordea, Rio Tinto PLC, Danske Bank A/S, Siemens, Capgemini SA, Total, Ryanair, Henkel, Barclays PLC, Continental AG, Allianz SE, Legrand, Weir Group, Tullow Oil, Philips, Alfa Laval, Ahold, Aegon NV, Michelin, Beiersdorf, Credit Suisse, Roche Holding AG, IMI, British Sky Broadcasting Group PLC, Smith & Nephew PLC, Tate and Lyle, Standard Life PLC, Schneider Electric, British American Tobacco PLC, AstraZeneca PLC, HeidelbergCement AG, LVMH, Assa Abloy, L'Air Liquide SA, Standard Chartered PLC, Daimler AG, International Consolidated Airlines Group, S.A., Renault SA, BNP Paribas SA, Shire Pharmaceuticals, Aviva PLC, KBC, ING Groep NV, BMW AG, Unilever NV, Reckitt Benckiser, Coloplast, HSBC Holdings PLC, EADS, Kering, GKN Plc, DNB ASA, ABB, Nokia Oyj,

Unilever PLC, SGS, Societe Generale, Seadrill, Actelion Ltd, Danone, Resolution, Kuehne & Nagel International, AXA SA, William Hill, Marks and Spencer Group PLC, Eni, Mondi Plc, Merck KGaA, BP, BHP Billiton PLC, Lloyds Banking Group PLC, Intertek, Deutsche Boerse AG, Randgold Resources Ltd, Atlas Copco, Syngenta AG, Novo Nordisk A/S, Royal Dutch Shell.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: WPP PLC, SAP AG, Swatch Group AG, SSE PLC, Deutsche Telekom AG, Smiths Group, Assicurazioni Generali SpA, Telefonica SA, Svenska Handelsbanken AB, Yara International, Royal Bank of Scotland Group PLC, Pernod-Ricard, Legal & General, Skandinaviska Enskilda Banken AB, Richemont, Essilor, Novartis AG, AB-InBev, Credit Agricole SA, Adecco, Prudential Plc, Bayer AG, Nestle, UBS, Sanofi SA, Intesa Sanpaolo, Aberdeen Asset Management, Melrose, Sodexo, Aggreko PLC, Valeo SA, Nordea, Rio Tinto PLC, Danske Bank A/S, Siemens, Capgemini SA, Total, Ryanair, Henkel, Barclays PLC, Continental AG, Allianz SE, Legrand, Tullow Oil, Philips, Alfa Laval, Ahold, Aegon NV, Michelin, Beiersdorf, Credit Suisse, Roche Holding AG, IMI, Dassault Systemes SA, Tate and Lyle, Standard Life PLC, Schneider Electric, Admiral Group, ITV PLC, British American Tobacco PLC, AstraZeneca PLC, HeidelbergCement AG, LVMH, Assa Abloy, L'Air Liquide SA, Standard Chartered PLC, Daimler AG, International Consolidated Airlines Group, S.A., Renault SA, BNP Paribas SA, Shire Pharmaceuticals, Aviva PLC, KBC, ING Groep NV, BMW AG, Unilever NV, Reckitt Benckiser, Coloplast, HSBC Holdings PLC, EADS, Kering, GKN Plc, DNB ASA, ABB, Nokia Oyj, Unilever PLC, SGS, Societe Generale, Seadrill, Actelion Ltd, Danone, Resolution, Kuehne & Nagel International, AXA SA, William Hill, Marks and Spencer Group PLC, Eni, Mondi Plc, Merck KGaA, BP, BHP Billiton PLC, Lloyds Banking Group PLC, Intertek, Deutsche Boerse AG, Randgold Resources Ltd, Atlas Copco, Syngenta AG, Next Group PLC, Novo Nordisk A/S, Royal Dutch Shell.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from ITV PLC.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

The Firm is a market maker in the publicly traded equity securities of Hargreaves Lansdown PLC, SSE PLC, Deutsche Telekom AG, Yara International, Pernod-Ricard, Legal & General, Bayer AG, Nestle, Sanofi SA, Intesa Sanpaolo, Sodexo, Valeo SA, Danske Bank A/S, Capgemini SA, Ryanair, Henkel, Barclays PLC, Continental AG, Allianz SE, Tullow Oil, Ahold, Roche Holding AG, IMI, Dassault Systemes SA, Tate and Lyle, Admiral Group, LVMH, L'Air Liquide SA, Daimler AG, BNP Paribas SA, Shire Pharmaceuticals, BMW AG, HSBC Holdings PLC, GKN Plc, SGS, Societe Generale, Danone, Resolution, AXA SA, Marks and Spencer Group PLC, Kingfisher PLC, Deutsche Boerse AG, Randgold Resources Ltd, Atlas Copco, Novo Nordisk A/S, ASML Holding NV.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Research Equity Ratings Distribution

<i>Data current as of 30 Sep 2013</i>	12 Month Rating			Relative Rating		
	Buy	Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage	48%	40%	12%	6%	87%	6%
% of companies in each rating category that are investment banking clients	55%	50%	43%	64%	51%	48%

Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

Investment Ratings: Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation.

Relative three-month ratings: Citi Research may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of the Citi Research expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis).

affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd

Anna Esposito; Jonathan Stubbs; Natalia Mamaeva; Jon H Bergtheil; Andrew S Baum; Andrew Coombs; Marc Van'T Sant; Andrew Light; Paul L Bradley; Michael J Alford; James Ainley; Andrew Benson; Richard Edwards; Philip Watkins; Ronit Ghose; Robert Coates; Thomas A Singlehurst, CFA; Toby McCullagh; Aynsley Lammin; Thomas Chauvet; Farooq Hanif; Kinner Lakhani; Amit B Harchandani; Roger Elliott; Jonathan Beake; Alastair R Syme; Robert Dickinson, CA; Ed Steele; Ryan W Kauppila; Simon Weeden; Assad M Malic; Nese Guner; Andrea Pistacchi; Joanne Jerman; Adam Spielman; Florent Nitu; Alastair A Johnston; Heath R Jansen; Georgios Ierodionou; Azzurra Guelfi; Stefan Nedialkov; Thomas Dörner; Chris Montagu

Citigroup Global Markets India Private Limited

Ayush Tambi; Devang Doshi

Citigroup Global Markets Inc

Jim Suva, CPA; Walter H Pritchard, CFA; Liav Abraham

Citigroup Global Markets (Pty) Ltd

Tassin Meyer

OTHER DISCLOSURES

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to SAP AG, Deutsche Telekom AG, Smiths Group, Telefonica SA, Svenska Handelsbanken AB, Yara International, Royal Bank of Scotland Group PLC, Pernod-Ricard, Legal & General, Skandinaviska Enskilda Banken AB, Essilor, AB-InBev, Credit Agricole SA, Adecco, Prudential Plc, Bayer AG, Nestle, UBS, Sanofi SA, Sodexo, Valeo SA, Rio Tinto PLC, Danske Bank A/S, Siemens, Total, Henkel, Barclays PLC, Continental AG, Allianz SE, Tullow Oil, Philips, Aegon NV, Credit Suisse, Roche Holding AG, Tate and Lyle, Standard Life PLC, Schneider Electric, British American Tobacco PLC, AstraZeneca PLC, HeidelbergCement AG, LVMH, Assa Abloy, L'Air Liquide SA, Daimler AG, Renault SA, BNP Paribas SA, Aviva PLC, ING Groep NV, BMW AG, Coloplast, EADS, Nokia Oyj, SGS, Societe Generale, Seadrill, Danone, AXA SA, Eni, Merck KGaA, BHP Billiton PLC, Lloyds Banking Group PLC, Deutsche Boerse AG, Randgold Resources Ltd, Syngenta AG, Novo Nordisk A/S. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citiVelocity.com.)

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Citigroup Global Markets Inc. or its affiliates acts as a corporate broker to Aggreko PLC, Ryanair, IMI, Tate and Lyle, William Hill, Marks and Spencer Group PLC, BHP Billiton PLC, Lloyds Banking Group PLC.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of

the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines**

through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the

client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
